212 related articles for article (PubMed ID: 32747712)
1. Engineered immunological niches to monitor disease activity and treatment efficacy in relapsing multiple sclerosis.
Morris AH; Hughes KR; Oakes RS; Cai MM; Miller SD; Irani DN; Shea LD
Nat Commun; 2020 Aug; 11(1):3871. PubMed ID: 32747712
[TBL] [Abstract][Full Text] [Related]
2. CXCL13 antibody for the treatment of autoimmune disorders.
Klimatcheva E; Pandina T; Reilly C; Torno S; Bussler H; Scrivens M; Jonason A; Mallow C; Doherty M; Paris M; Smith ES; Zauderer M
BMC Immunol; 2015 Feb; 16(1):6. PubMed ID: 25879435
[TBL] [Abstract][Full Text] [Related]
3. Antibody-mediated inhibition of TNFR1 attenuates disease in a mouse model of multiple sclerosis.
Williams SK; Maier O; Fischer R; Fairless R; Hochmeister S; Stojic A; Pick L; Haar D; Musiol S; Storch MK; Pfizenmaier K; Diem R
PLoS One; 2014; 9(2):e90117. PubMed ID: 24587232
[TBL] [Abstract][Full Text] [Related]
4. MicroRNAs in multiple sclerosis and experimental autoimmune encephalomyelitis.
Thamilarasan M; Koczan D; Hecker M; Paap B; Zettl UK
Autoimmun Rev; 2012 Jan; 11(3):174-9. PubMed ID: 21621006
[TBL] [Abstract][Full Text] [Related]
5. Hematopoietic stem cell transplantation in multiple sclerosis: experimental evidence to rethink the procedures.
Karussis D; Slavin S
J Neurol Sci; 2004 Aug; 223(1):59-64. PubMed ID: 15261562
[TBL] [Abstract][Full Text] [Related]
6. Gene Therapy Approaches in an Autoimmune Demyelinating Disease: Multiple Sclerosis.
Islam MA; Kundu S; Hassan R
Curr Gene Ther; 2020; 19(6):376-385. PubMed ID: 32141417
[TBL] [Abstract][Full Text] [Related]
7. Immune-based therapy of multiple sclerosis.
Kaufman MD
N C Med J; 1995 Aug; 56(8):379-84. PubMed ID: 7566191
[No Abstract] [Full Text] [Related]
8. Epithelial V-like antigen mediates efficacy of anti-alpha₄ integrin treatment in a mouse model of multiple sclerosis.
Wright E; Rahgozar K; Hallworth N; Lanker S; Carrithers MD
PLoS One; 2013; 8(8):e70954. PubMed ID: 23951051
[TBL] [Abstract][Full Text] [Related]
9. Pathogenic mechanisms and experimental models of multiple sclerosis.
Slavin A; Kelly-Modis L; Labadia M; Ryan K; Brown ML
Autoimmunity; 2010 Nov; 43(7):504-13. PubMed ID: 20380590
[TBL] [Abstract][Full Text] [Related]
10. Modelling of multiple sclerosis: lessons learned in a non-human primate.
't Hart BA; Laman JD; Bauer J; Blezer E; van Kooyk Y; Hintzen RQ
Lancet Neurol; 2004 Oct; 3(10):588-97. PubMed ID: 15380155
[TBL] [Abstract][Full Text] [Related]
11. Natural killer T cells in multiple sclerosis and its animal model, experimental autoimmune encephalomyelitis.
Van Kaer L; Wu L; Parekh VV
Immunology; 2015 Sep; 146(1):1-10. PubMed ID: 26032048
[TBL] [Abstract][Full Text] [Related]
12. Depletion of CD52-positive cells inhibits the development of central nervous system autoimmune disease, but deletes an immune-tolerance promoting CD8 T-cell population. Implications for secondary autoimmunity of alemtuzumab in multiple sclerosis.
von Kutzleben S; Pryce G; Giovannoni G; Baker D
Immunology; 2017 Apr; 150(4):444-455. PubMed ID: 27925187
[TBL] [Abstract][Full Text] [Related]
13. Transplantation of autologous adipose stem cells lacks therapeutic efficacy in the experimental autoimmune encephalomyelitis model.
Zhang X; Bowles AC; Semon JA; Scruggs BA; Zhang S; Strong AL; Gimble JM; Bunnell BA
PLoS One; 2014; 9(1):e85007. PubMed ID: 24465465
[TBL] [Abstract][Full Text] [Related]
14. T-cell based immunotherapy in experimental autoimmune encephalomyelitis and multiple sclerosis.
O'Brien K; Gran B; Rostami A
Immunotherapy; 2010 Jan; 2(1):99-115. PubMed ID: 20231863
[TBL] [Abstract][Full Text] [Related]
15. [Experimental autoimmune encephalomyelitis].
Cornet A; Vizler C; Liblau R
Rev Neurol (Paris); 1998 Sep; 154(8-9):586-91. PubMed ID: 9809373
[TBL] [Abstract][Full Text] [Related]
16. Monoclonal antibody therapy in experimental allergic encephalomyelitis and multiple sclerosis.
Zhang X; Hupperts R; De Baets M
Immunol Res; 2003; 28(1):61-78. PubMed ID: 12947225
[TBL] [Abstract][Full Text] [Related]
17. Pathogenesis of neuroimmunologic diseases. Experimental models.
Constantinescu CS; Hilliard B; Fujioka T; Bhopale MK; Calida D; Rostami AM
Immunol Res; 1998; 17(1-2):217-27. PubMed ID: 9479583
[TBL] [Abstract][Full Text] [Related]
18. Suppression of chronic allergic encephalomyelitis: relevance to multiple sclerosis.
Raine CS; Traugott U; Stone SH
Science; 1978 Aug; 201(4354):445-8. PubMed ID: 78524
[TBL] [Abstract][Full Text] [Related]
19. Anti-CD48 Monoclonal Antibody Attenuates Experimental Autoimmune Encephalomyelitis by Limiting the Number of Pathogenic CD4+ T Cells.
McArdel SL; Brown DR; Sobel RA; Sharpe AH
J Immunol; 2016 Oct; 197(8):3038-3048. PubMed ID: 27581174
[TBL] [Abstract][Full Text] [Related]
20. A network analysis of the human T-cell activation gene network identifies JAGGED1 as a therapeutic target for autoimmune diseases.
Palacios R; Goni J; Martinez-Forero I; Iranzo J; Sepulcre J; Melero I; Villoslada P
PLoS One; 2007 Nov; 2(11):e1222. PubMed ID: 18030350
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
